Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Malin completes asset purchases, confirms management changes

Published 24/08/2015, 10:36
© Reuters.  Malin completes asset purchases, confirms management changes

By Padraic Halpin

DUBLIN (Reuters) - Irish life sciences investment firm Malin (I:MLCM) completed its initial series of asset purchases with two more investments on Monday and said director and former Elan boss Kelly Martin would take over as chief executive.

Malin was set up this year by executives from former Irish drugmaker Elan and raised 330 million euros (241 billion pounds) in one of Europe's biggest biotechnology initial public offerings (IPO) to invest in smaller, unlisted firms.

After spending the proceeds ahead of schedule, Malin said CEO Adrian Howd, a former equity analyst with a doctorate in molecular neuroscience, would assume the new role of Chief Investment Officer to concentrate on the clinical progression of the assets.

"Into the next phase, it's all about the assets. We stepped back and looked at how we can help progress those assets," Malin Chairman John Given, who will also take on some executive functions, told Reuters.

"We have a world class scientist and analyst in Adrian who is in a unique position to do that and we also have an operational CEO effectively on the bench, Kelly Martin."

Martin, a former Merrill Lynch banker who took over at Elan in the midst of an accounting scandal in 2003 before cleaning it up and selling it to Perrigo (N:PRGO) for $8.6 billion (5.5 billion pounds) a decade later, will take over the day-to-day operations of the company.

Two sources told Reuters on Sunday that Martin was set to be appointed to the role.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Malin made the announcement after detailing its final main investments, including a minimum of $15 million (9.5 million pounds), or up to $20 million (12.7 million pounds) depending on a number of factors, committed to North Carolina-based Hatteras Venture Partners (HVP).

Malin said the deal would allow it to extend its network without building out its own infrastructure by leveraging HVP's expertise in early stage discovery science, medical device and diagnostics.

It also committed up to $1 million in New York-based Jaan Health, a privately held healthcare mobile technology company.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.